735 related articles for article (PubMed ID: 16988594)
1. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.
Tomida I; Azuara-Blanco A; House H; Flint M; Pertwee RG; Robson PJ
J Glaucoma; 2006 Oct; 15(5):349-53. PubMed ID: 16988594
[TBL] [Abstract][Full Text] [Related]
2. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.
Johnson JR; Burnell-Nugent M; Lossignol D; Ganae-Motan ED; Potts R; Fallon MT
J Pain Symptom Manage; 2010 Feb; 39(2):167-79. PubMed ID: 19896326
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of topical 0.05% flunarizine in patients with open-angle glaucoma or ocular hypertension-a pilot study.
Mansouri K; Silva SE; Shaarawy T
J Glaucoma; 2011 Oct; 20(8):519-22. PubMed ID: 21048514
[TBL] [Abstract][Full Text] [Related]
5. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.
Roser P; Juckel G; Rentzsch J; Nadulski T; Gallinat J; Stadelmann AM
Eur Neuropsychopharmacol; 2008 Aug; 18(8):569-77. PubMed ID: 18544469
[TBL] [Abstract][Full Text] [Related]
6. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
8. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma.
Konstas AG; Tsironi S; Vakalis AN; Nasr MB; Stewart JA; Nelson LA; Stewart WC
Acta Ophthalmol; 2009 Feb; 87(1):71-6. PubMed ID: 19178390
[TBL] [Abstract][Full Text] [Related]
9. Topical and oral ketorolac administration increases the intraocular pressure-lowering effect of latanoprost.
Costagliola C; Campa C; Perri P; Parmeggiani F; Romano MR; Incorvaia C
Curr Eye Res; 2008 May; 33(5):477-82. PubMed ID: 18568885
[TBL] [Abstract][Full Text] [Related]
10. Duration of IOP reduction with travoprost BAK-free solution.
Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
[TBL] [Abstract][Full Text] [Related]
12. Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits.
Mannila J; Järvinen T; Järvinen K; Tarvainen M; Jarho P
Eur J Pharm Sci; 2005 Sep; 26(1):71-7. PubMed ID: 15955678
[TBL] [Abstract][Full Text] [Related]
13. Intraocular pressure elevation within the first 24 hours after cataract surgery in patients with glaucoma or exfoliation syndrome.
Levkovitch-Verbin H; Habot-Wilner Z; Burla N; Melamed S; Goldenfeld M; Bar-Sela SM; Sachs D
Ophthalmology; 2008 Jan; 115(1):104-8. PubMed ID: 17561259
[TBL] [Abstract][Full Text] [Related]
14. Effect of beclomethasone nasal spray on intraocular pressure in ocular hypertension or controlled glaucoma.
Yuen D; Buys YM; Jin YP; Alasbali T; Trope GE
J Glaucoma; 2013 Feb; 22(2):84-7. PubMed ID: 21716127
[TBL] [Abstract][Full Text] [Related]
15. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure.
Toris CB; Zhan G; Fan S; Dickerson JE; Landry TA; Bergamini MV; Camras CB
J Glaucoma; 2007 Mar; 16(2):189-95. PubMed ID: 17473728
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
[TBL] [Abstract][Full Text] [Related]
17. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
Yildirim N; Sahin A; Gultekin S
J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382
[TBL] [Abstract][Full Text] [Related]
18. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials.
Varma R; Hwang LJ; Grunden JW; Bean GW
Am J Ophthalmol; 2008 Feb; 145(2):336-42. PubMed ID: 18222194
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.
Williams RD; Cohen JS; Gross RL; Liu CC; Safyan E; Batoosingh AL;
Br J Ophthalmol; 2008 Oct; 92(10):1387-92. PubMed ID: 18621791
[TBL] [Abstract][Full Text] [Related]
20. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure.
Koseki N; Araie M; Tomidokoro A; Nagahara M; Hasegawa T; Tamaki Y; Yamamoto S
Ophthalmology; 2008 Nov; 115(11):2049-57. PubMed ID: 18672290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
